Novin Plasma’s primary focus is on the production of medicines derived from human plasma, a rich source of essential proteins. Patients throughout Iran and around the world rely on plasma medicines to treat rare and life-threatening conditions such as immune deficiencies, hemophilia, and genetic emphysema. Our plasma fractionation plant, the first in Iran, will consist of more than 200 highly qualified scientists, technical professionals, and sales representatives who will all contribute to the production and distribution of plasma protein products from a facility with an initial capacity to process 750,000 liters of plasma annually. Our plasma fractionation facility will be equipped with state-of-the-art filling and packaging areas to finalize bulk products for commercial use. We take pride in our innovative achievements and adherence to the highest standards of honesty and professional ethics. We have an unwavering commitment to the development of safer and more effective blood and plasma therapies as well as innovative products designed for hospitals, laboratory professionals and healthcare providers.